Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
As financial institutions grapple with aging core systems like Gen, experts warn that deferring modernization in hopes of a future AI fix is compounding costs, risks, and missed opportunities in a rapidly evolving digital landscape.
While analyst price targets often paint a rosy picture, a closer look reveals a more nuanced reality. We examine one favored stock with solid fundamentals and two others where the Street's optimism may be overlooking critical risks.
In a rare break from Wall Street's typically optimistic consensus, a handful of prominent stocks are receiving bearish price targets that signal deep-seated concerns. We examine the challenges facing Deckers, MSC Industrial, and Guardant Health, and why investors might want to look elsewhere.
The construction and maintenance services industry delivered a robust third quarter, with several key players exceeding revenue expectations despite economic headwinds. MYR Group and Comfort Systems stood out with strong beats, while the sector overall demonstrated pricing power and steady demand.
As major U.S. banks wrap up their fourth-quarter earnings, a clear divergence emerges. While PNC and Bank of America post strong results, Citigroup and JPMorgan Chase face headwinds. Truist Financial charts a middle course, meeting revenue expectations as the sector navigates a complex economic landscape.
India's government has reaffirmed its stringent cryptocurrency taxation framework in the latest budget, leaving the controversial 30% levy and 1% transaction tax unchanged, dashing industry hopes for reform and cementing a policy that has already driven billions in trading volume offshore.
As Zurn Elkay Water Solutions prepares to report its quarterly results, investors are watching to see if the company can extend its impressive track record of exceeding revenue forecasts. We break down the key figures, peer performance, and market sentiment heading into the announcement.
Global insurer Chubb Limited prepares to release its fourth-quarter financial results after Tuesday's market close, with investors weighing solid peer performances against broader sector headwinds.
While low-volatility stocks can anchor a portfolio, investors often sacrifice growth for safety. We analyze one steady performer with durable advantages and two companies where challenges may outweigh the stability premium.
As several stocks test their 52-week highs, we separate resilient momentum from potential mirages. We analyze one company capitalizing on long-term trends and two where caution may be warranted.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
Northwest Bancshares' Q4 results showcased the initial impact of its Penns Woods acquisition, boosting revenue and margins. While management struck a confident tone on integration, analyst questions during the earnings call revealed a sharper focus on the sustainability of growth, cost savings, and competitive pressures in a shifting rate environment.
Singapore will establish its National Space Agency on April 1st, aiming to leverage its technological prowess to secure a strategic position in the rapidly expanding global space economy, as global investments continue to soar.
FirstSun Capital Bancorp's fourth-quarter results surpassed analyst forecasts, driven by robust net interest margins and loan growth. However, the post-earnings call revealed deeper questions from analysts about the sustainability of its performance and integration challenges.
NBT Bancorp met Q4 earnings expectations, driven by its Evans Bancorp merger and wealth management income. While the market reaction was muted, analysts pressed management on loan growth sustainability, deposit costs, and the competitive landscape in a challenging rate environment.
Satellite communications provider Viasat (VSAT) saw its shares hit a new 52-week peak of $46.49, capping a remarkable 12-month rally. The surge follows a significant price target upgrade from Morgan Stanley and the successful launch of a key global network for government clients.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Aerospace systems provider Astronics Corporation launches its new automated circuit card testing system, designed to accelerate troubleshooting and maintenance for critical aviation and defense electronics, as analysts raise price targets on sustained sector demand.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
